In contrast, activation of hepatic KISS1R using a potent KP agonist (KPA) protected against the development of hepatic steatosis and was found to reduce progression to NASH and hepatic fibrosis. This evidence concerns the gene KISS1R and metabolic dysfunction-associated steatohepatitis.